Selvacovatein
Highest phase reached
Approved
Drug type
Protein
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Selvacovatein
- bimervax
- Bimervax
- bimervax
- BIMERVAX
- selvacovatein
- Selvacovatein
- selvacovateina
- Selvacovateina
- selvacovateine
- Selvacovateine
- ChEMBL ID
- CHEMBL5314796
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Spike glycoprotein
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- COVID-19
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
Open Targets indications
- Condition identifier
- MONDO_0100096
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 13 $ 25 $ 232 $ 244
- Component
- Sequence
- Type
- Protein
- Sequence
- RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK
- Component
- Disulfide bridges
- Sequence
- 18-43 $ 61-114 $ 73-207 $ 162-70 $ 237-262 $ 280-333 $ 292-426 $ 381-389
Related records
Trials (2)
- A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
- Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.